UNITED STATES SECURITIES

AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________

FORM 6-K

________________________

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of October 2023

Commission File Number: 001-38281

________________________

PHAXIAM Therapeutics S.A.

(Translation of registrant’s name into English)

________________________

60 Avenue Rockefeller

69008 Lyon France

(Address of principal executive office)

________________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F S Form 40-F £

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

Press Release dated October 923, 2023

On October 923, 2023, Phaxiam Therapeutics S.A. issued a press release announcing athat ~~very~~TP ~~high~~ICAP ~~spectrum~~Midcap, ofa ~~activity~~brokerage offirm ~~its~~and ~~anti-S.aureus~~investment ~~(PP1493~~bank specializing in small and ~~PP1815)~~mid-caps, ~~phages~~has ~~against~~initiated ~~clinical~~coverage ~~bacterial~~of ~~strains~~its shares.

~~The~~Press ~~full~~Release ~~text~~dated ofOctober ~~the~~24, ~~press release is attached as Exhibit 99.1 to this Report on Form 6-K and incorporated herein by reference.~~2023

On October 24, 2023, Phaxiam Therapeutics S.A. issued a press release announcing the approval of its phase 1 study clinical design in endocarditis infections caused by Staphylococcus aureus (S. aureus) by the French National Agency for the Safety of Medicines and Health Products (ANSM) and the South-East II-Lyon Ethics Committee (Comité de Protection des Personnes - CPP).

The full text of the press releases are attached as Exhibit 99.1 and Exhibit 99.2 to this Report on Form 6-K and incorporated herein by reference.

EXHIBITS

Exhibit						Description
99.1						Press Release dated October 923, 2023.
99.2						Press Release dated October 24, 2023

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PHAXIAM Therapeutics S.A.

Date:

October 1125, 2023

By:

/s/ Eric Soyer

Name Eric Soyer

Title: Deputy Chief Executive Officer, Chief Financial Officer and Chief Operating Officer

Filing Compare · PHAXIAM Therapeutics S.A.